---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052094"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:26:20.863293+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q1 revenue $19.3M (+2% YoY); wins $34M jury verdict against Alcon

## Summary
- Q1 2024 revenue $19.3M (+2% YoY); Surgical Glaucoma $18.3M (+5%), Dry Eye $1.0M (-32%).
- Net loss $16.3M ($0.33/share) vs $17.1M ($0.35/share); gross margin 86% vs 84% prior year.
- Jury found willful infringement by Alcon; awards $5.5M lost profits + $28.5M royalty for Hydrus Microstent.
- Reaffirms FY2024 revenue guidance $81M-$85M (0-5% growth) and adjusted op ex $107M-$110M.
- Cash burn reduced to $10.8M (incl. $3.2M debt restructuring costs) from $17.7M in Q1 2023.

## SEC filing metadata
- accession: 0000950170-24-052094
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/0000950170-24-052094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/sght-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052094
- JSON: https://secwatch.observer/filing/0000950170-24-052094.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052094.txt

## Key facts
- Earnings Releases
  Sight Sciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $19.3 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $19.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year. • Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/0000950170-24-052094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.